EphemerisXResearch

Complete Response Letters

Galderma R&D, LLC: BLA 761311

What FDA's Complete Response Letters to the company say, in the letters' own words.

EphemerisX Research · Sep 30, 2026 · Sources: FDA, SEC

Complete Response Letter, Sep 29, 2023

You may also submit a Request for Proprietary Name Review to your IND in the interim.
Complete Response Letter · Sep 29, 2023 · p. 23Open the letter at p. 23 ↗CRL_BLA761311_20230929:p2:s19

More Complete Response Letters

All companies in the CRL Tracker →

Updated Sep 30, 2026 · built from 283 companies in the EphemerisX knowledge graph. This page is regenerated as companies are added.